Vincerx Pharma, Inc. Common Stock (VINC) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Vincerx Pharma, Inc. Common Stock (VINC) has a cash flow conversion efficiency ratio of -2.156x as of March 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-4.45 Million) by net assets ($2.07 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Vincerx Pharma, Inc. Common Stock stock valuation for the company's overall valuation and market capitalisation.
Vincerx Pharma, Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how Vincerx Pharma, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Vincerx Pharma, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Vincerx Pharma, Inc. Common Stock ranked by their cash flow conversion efficiency. See Vincerx Pharma, Inc. Common Stock (VINC) cash flow to debt to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
ECR Minerals plc
LSE:ECR
|
0.041x |
|
Petards Group plc
LSE:PEG
|
0.129x |
|
Thor Mining PLC
LSE:THR
|
-0.058x |
|
Novo Integrated Sciences Inc
NASDAQ:NVOS
|
-0.037x |
|
Jangada Mines Plc
LSE:JAN
|
-0.090x |
|
Touchstar plc
LSE:TST
|
0.662x |
|
Blackbird PLC
LSE:BIRD
|
-0.118x |
|
Comptoir Group PLC
LSE:COM
|
11.244x |
Annual Cash Flow Conversion Efficiency for Vincerx Pharma, Inc. Common Stock (2019–2024)
The table below shows the annual cash flow conversion efficiency of Vincerx Pharma, Inc. Common Stock from 2019 to 2024. View today's stock price for Vincerx Pharma, Inc. Common Stock for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $2.72 Million | $-26.13 Million | -9.591x | -166.07% |
| 2023-12-31 | $11.22 Million | $-40.45 Million | -3.605x | -188.29% |
| 2022-12-31 | $47.67 Million | $-59.60 Million | -1.250x | -275.55% |
| 2021-12-31 | $100.32 Million | $-33.40 Million | -0.333x | -742.78% |
| 2020-12-31 | $57.69 Million | $-2.28 Million | -0.040x | -104.85% |
| 2019-12-31 | $-43.00K | $-35.00K | 0.814x | -- |
About Vincerx Pharma, Inc. Common Stock
Vincerx Pharma, Inc. operates as a clinical-stage biopharmaceutical company that develops differentiated and novel therapies to address the unmet medical needs of patients with cancer in the United States. Its VersAptx bioconjugation platform combines different targeting, linker, and payload technologies to develop antibody-drug conjugates (ADC) and small molecule drug conjugates (SMDC); and prov… Read more